Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Prohost Letter #402

November 30, 2016 0

Prohost Letter #402 Antisense Proof of Concept and Feasibility EYE ON INVIVA (INVA) Sales of The …

It Is All About Array Biopharma

November 22, 2016 0

Prohost Biotech On ARRAY PHARMACEUTICALS Under the title “Halozyme has Good News and Array Too”, we …

Prohost Letter #401

November 16, 2016 0

Prohost Letter #401 SYNOPSIS PART 1 In this Letter CONTENTS Duchenne Muscular Dystrophy (DMD) FDA Compassionate …

Adaptimmune: The FDA Removed the Temporary Ban on the Trial with NY-ESOS PEAR T-Cell Therapy for Mixoid Round Cell Liposarcoma

November 14, 2016 0

The U.S. Food and Drug Administration (FDA) has removed the partial clinical hold it put on …

PTC Therapeutics Stock Price Doubles. When the Data Are Not Good for Forecasting.

November 11, 2016 0

The media failure to forecast the results of the Presidential election has become the talk of …

Ionis Drug Spinraza Conquers Spinal Muscular Atrophy with Statistically Significant Results

November 8, 2016 0

Biogen (BIIB) and Ionis (IONS) announced that Spinraza (nusinersen), an antisense drug designed and developed by …

Cempra Stock has Been Cremated. Will Today’s Good News Resurrect It?

November 7, 2016 0

The nature the Presidential Election this time is weighing on investors’ chests and minds and mood …

Ariad Pharmaceuticals: Substantiating Its Solid Scientific Fundamentals and the Value of Its Strategy

November 1, 2016 0

Ariad Pharmaceuticals (ARIA): Good news from the U.S. Food and Drug Administration (FDA) affirmed that the …

Regeneron and Sanofi Rheumatoid Arthritis Drug is Still Extremely Promising

October 31, 2016 0

Regeneron (REGN) and Sanofi informed that the FDA has issued a Complete Response Letter (CRL) regarding …

Prohost Letter #400

October 27, 2016 0

Prohost Letter #400 NEAR-TERM INVESTING The Prohost Letter #399 Part 3 has Promised to Des

Gilead’s Positive News Exceeds By-Far Its Negative News. Who Said Gilead Needs Acquisitions to Maintain Its Growth?

October 21, 2016 0

Results from trials were negative in two phase 2 studies for Gilead (GILD) experimental drug GS-4997 …

Why We Are Ignoring the Temporary Selling of NKTR. See Also: Agenus Adjuvant in GSK Successful Shingles Vaccine

October 19, 2016 0

There is nothing wrong with Nektar Therapeutics (NKTR). The stock is temporarily underperforming as traders are …

Incyte and Lilly: Conquering Rheumatoid Arthritis

October 18, 2016 0

At the Annual European Congress of Rheumatology (EULAR 2016) in London, Eli Lilly and Company (LLY) …

Senator Sanders and Ariad

October 17, 2016 0

Shares of Ariad Pharmaceuticals declined following Senator Bernie Sanders’ criticism of the high price of the …

A Promising Strategic Agreement Between a Large and a Small Biotech Firms

October 13, 2016 0

When plenty of news comes out of the biotech sector, we are left with no option …

Exelixis: A Sunny Future

October 12, 2016 0

EXELIXIS APPROVED PRODUCTS 1. CABOMETYX™(CABOZANTINIB) For Exelixis (EXEL) the two approved oncology products cabozantinib and cobimetinib …

Alnylam: Some Acted Without Listening and Some Listened But Did Not Believe

October 6, 2016 0

Following recent reports of new onset or worsening peripheral neuropathy in patients with ATTR amyloidosis with …

A Breakthrough Drug for Severe Eczema

October 4, 2016 0

News about investigational drugs, which are expected to make big differences in the lives of people …

Exelixis: What should We Do Now?

September 29, 2016 0

EXELIXIS (EXEL) Friends and subscribers are asking the following question for more than two weeks now: …

Sarepta: Will the Celebration of the Unexpected Approval Be of a Long Duration?

September 22, 2016 0

The FDA approval of Sarepta’s (SRPT) Duchenne muscular dystrophy (DMD) product, Exondys 51 (eteplirsen), surprised many …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd